Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The power of drug samples

Executive Summary

Drug samples provided to doctors by brand firms are "probably the biggest thwart on improving generic fill rate," Excellus Blue Cross Blue Shield Chief Pharmacy Officer Joel Owerbach said at an April 9 briefing on generic drug utilization sponsored by the BCBS Association. Samples, which brand firms say can help reduce costs for needy patients and serve as emergency supplies during catastrophes, are becoming an increasing focus of detailing now that the PhRMA marketing code has limited the other items, such as pens or lunches, that firms can provide physicians (1"The Pink Sheet," March 30, 2009, p. 13)

You may also be interested in...



Coupon Redemption On The Rise: A Recession-Proof Boost For Scripts?

Coupon redemptions for prescription drugs more than doubled in 2008 compared to 2007, according to a telephone and internet study of 8,700 consumers conducted by Manhattan Research, a research division of Decision Resources

EU Crunch Time For Two Drugs That Lost Their Fast-Track Status

Karyopharm and GSK should soon learn whether the European Medicines Agency will recommend EU approval for their respective products, selinexor and dostarlimab.

Novartis Holds Out For Happier Second Half Of 2020

The fourth quarter proved to be challenging for Novartis, with its dermatology, ophthalmology and oncology products – and Zolgensma – feeling the impact of COVID-19 lockdowns. The company is hoping for much better things in the second part of 2021.

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel